Sort by

Send to

Choose Destination

Search results

Items: 5


Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.

Yang W, Hosford SR, Traphagen NA, Shee K, Demidenko E, Liu S, Miller TW.

FASEB J. 2018 Mar;32(3):1222-1235. doi: 10.1096/fj.201700477R. Epub 2018 Jan 3.


Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer.

Hosford SR, Dillon LM, Bouley SJ, Rosati R, Yang W, Chen VS, Demidenko E, Morra RP Jr, Miller TW.

Clin Cancer Res. 2017 Jun 1;23(11):2795-2805. doi: 10.1158/1078-0432.CCR-15-2764. Epub 2016 Nov 30.


Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.

Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW.

Clin Cancer Res. 2016 May 1;22(9):2250-60. doi: 10.1158/1078-0432.CCR-15-2276. Epub 2016 Jan 5.


The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.

Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW.

Breast Cancer Res Treat. 2015 Jan;149(1):69-79. doi: 10.1007/s10549-014-3201-6. Epub 2014 Dec 10.


Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.

Hosford SR, Miller TW.

Pharmgenomics Pers Med. 2014 Aug 6;7:203-15. doi: 10.2147/PGPM.S52762. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center